iBio partners with AstralBio to develop obesity treatments using AI-driven platformProactive Investors • Wednesday
iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic DiseasesGlobeNewsWire • Wednesday
Top 4 Health Care Stocks That May Rocket Higher In Q1 - AlloVir (NASDAQ:ALVR), GRI Bio (NASDAQ:GRI)Benzinga • 01/16/24
iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 BispecificGlobeNewsWire • 11/01/23
iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical DevelopmentGlobeNewsWire • 08/14/23
iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of GrowthGlobeNewsWire • 06/27/23
iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering PlatformGlobeNewsWire • 04/04/23